James Galloway
@drjamesgalloway
Followers
1K
Following
438
Media
22
Statuses
1K
Epidemiologist, Lecturer, Rheumatologist in London.
London, UK
Joined June 2011
Tofacitinib in 15 pts w/ early diffuse skin Scleroderma. Tofa downregulated STAT3 (macrophages, DCs) & IFN (fibroblasts) & MYOC/CCL19 (adventitial fibroblasts); well tolerated & trend to improved mRSS scores (ns) https://t.co/Vt25ui8GwF
1
16
57
Is PMR the Next Indication for Tocilizumab? About half of patients with steroid-dependent PMR were able to get off steroids altogether when they were started on tocilizumab (Actemra) infusions, a randomized phase III trial showed. https://t.co/fe8d6LNMOh
1
4
13
🏥 Today, we're proud to unveil the new rooftop of the Denmark Wing building at King's College Hospital! #TeamKings #TuesdayMotivation
8
9
170
AURORA 2 results were presented at #ACR21 - a continuation study of voclosporin in 116 active Lupus Nephritis pts randomized to either PBO or voclosporin. After 36 mos the VOC group had stable GFR and reduction in proteinuria
businesswire.com
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the course ...
0
3
8
And the @asmeofficial meeting in glorious Aberdeen (bias alert 🏴) abstract deadline is 31/1 https://t.co/iQbKTYiktR
@KathyMCullen1 @drjamesgalloway @OneLongPlait
0
1
1
NEW: D’Agostino et al. use Power Doppler #ultrasound to investigate the response of synovitis to IL-17A inhibition with secukinumab in patients with active PsA. Watch Prof D’Agostino provide an overview of the study in our first video abstract 🤩 👉 https://t.co/upQVoAtIh1
0
2
2
Two new papers published in @RheumJnl today look @ the impact of #COVID19 & #lockdown measures on #rheumatology patients in the UK & Europe: Inflammatory #arthritis: https://t.co/rUYvJ6f5LB RMDs: https://t.co/poQ8Q94VDl Available #openaccess
0
5
7
News: EULAR Guidelines on Intraarticular Therapy EULAR has published evidence-based recommendations on the use of intra-articular therapies (IAT) based on the literature review and recommendations of a multidisciplinary international task force. https://t.co/Z6vC0x9zY1
4
19
52
@RheumJnl Thank you for joining us today! #RheumJnlClub #InternationalNursesDay a double celebration!
0
1
3
Curiously not even SPARCC captures spinal entheseal points. Interesting thought.
@drjamesgalloway @drdj I think an index which also includes the axial enthesal sites would be more comprehensive. Guselkumab is anyway likely to benefit more of peripheral enthesal sites than axial #Rheumjnlclub
0
0
0
@RheumJnl Hey everyone, this is Fabian a rheumatologist from Berlin Germany with a special interest in axSpA and PsA especially new treatment options, RCT‘s, cohort studies and modern imaging modalities. #RheumJnlClub
1
1
2
Head to head studies that separate out MDA components- definitely. Very good point @ProftDr
@RheumJnl These pooled data looks really promising. But so far we are not sure of the relevance in the current treatment landscape. Really looking forward to H2H trials. Most interesting vs. IL-17A-inhibition ☝️
0
1
0
@RheumJnl @drjamesgalloway It would have probably been more significant using a more comprehensive measure
0
2
1
Agree
0
0
1
Interesting question. Its hinges on your interpretation of the figure 4 in the paper. My sense is that enthesitis response does correlate with the overall response but it is by no means an absolute parallel…
How much overlap was there between enthesitis response and clinical response? Does one always predict the other? #RheumJnlClub
0
1
3
How much overlap was there between enthesitis response and clinical response? Does one always predict the other? #RheumJnlClub
0
2
4
@RheumJnl Do we also have any data on imaging proven enthesitis? NB: what we discuss here is more clinical enthesiopathy from my point of view
0
2
2